UCB nears fourth EU nod for Bimzelx, this time in hidradenitis suppurativa

22 Mar 2024
firstwordpharma.com
Phase 3Drug ApprovalClinical Result
A drug review committee for the European Medicines Agency (EMA) recommended approval of UCB’s Bimzelx (bimekizumab) for hidradenitis suppurativa (HS) on Friday, moving the antibody one step closer to clinching its fourth approval in the EU.
The dual IL-17A and IL-17F inhibitorIL-17F inhibitor is already approved by the EMA to treat plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. Last year, Bimzelx scored a long-awaited FDA approval for psoriasis (see – KOL Views Q&A: Early look at how UCB’s Bimzelx is faring in battle with IL-17s and IL-23s in psoriasis).
The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Bimzelx based on two Phase III trials, BE HEARD I and BE HEARD II.
The studies enrolled 1014 patients with moderate-to-severe HS to receive a Bimzelx injection either every two weeks, every four weeks, or placebo.
At week 16, Bimzelx led to statistically significant and clinically meaningful improvements over placebo as measured by Hidradenitis Suppurativa Clinical Response (HiSCR50), meeting the primary endpoint.
If approved, Bimzelx would become the third therapy available for HS patients in the EU, following AbbVie’s Humira (adalimumab) and Novartis’ Cosentyx (secukinumab). More options could be on the horizon, however, as the next generation of HS treatments, which are directed against several new targets, reach late-stage testing. For more, see KOL Views Q&A: Leading dermatologist optimistic about next wave of HS treatments.
A greenlight in HS could also help UCB reach its estimated peak sales of at least €4 billion ($4.2 billion) for Bimzelx.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.